FDA approves Regeneron's antibody for rare immune disease, resolves manufacturing issues for aflibercept
The FDA approved Regeneron’s pozelimab, the first treatment for a rare, hereditary immune disease that affects fewer than 100 people worldwide.
The monoclonal antibody, to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
